Australia - angielski - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - lansoprazole, quantity: 15 mg - tablet, orally disintegrating - 15 mg - excipient ingredients: iron oxide yellow; polysorbate 80; purified talc; microcrystalline cellulose; titanium dioxide; lactose monohydrate; aspartame; hyprolose; macrogol 8000; iron oxide red; magnesium carbonate hydrate; magnesium stearate; crospovidone; mannitol; glyceryl monostearate; hypromellose; triethyl citrate; citric acid; polyacrylate dispersion (30 per cent); purified water; methacrylic acid copolymer; sodium lauryl sulfate; flavour - adults 1. healing and long-term management of reflux oesophagitis. 2. healing and long-term management for patients with duodenal ulcer. 3. healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 4. lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. 5. eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). 6. relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. paediatric patients 6 to 17 years of age. 1. treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. 2. healing of erosive oesophagitis.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - montelukast sodium, quantity: 4.16 mg - tablet, chewable - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; mannitol; magnesium stearate; iron oxide red; aspartame; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - montelukast sodium, quantity: 5.2 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; mannitol; magnesium stearate; iron oxide red; aspartame; flavour - -prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. ,-symptomatic treatment of seasonal allergic rhinitis.

Singapur - angielski - HSA (Health Sciences Authority)

organon singapore pte. ltd. - montelukast sodium 10.4 mg eqv montelukast (core tablet) - tablet - 10 mg - montelukast sodium 10.4 mg eqv montelukast (core tablet) 10 mg

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - enrofloxacin - tablet - 15 mg/tablet - enrofloxacin - cats, dogs - antibacterial

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - enrofloxacin - tablet - 150 mg/tablet - enrofloxacin - dogs - antibacterial

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - enrofloxacin - tablet - 50 mg/tablet - enrofloxacin - dogs - antibacterial

Australia - angielski - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - escitalopram oxalate, quantity: 25.548 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; maize starch; magnesium stearate; mannitol; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000 - treatment of major depression. ,treatment of social anxiety disorder (social phobia). ,treatment of generalised anxiety disorder. ,treatment of obsessive-compulsive disorder.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - escitalopram oxalate, quantity: 12.774 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; mannitol; titanium dioxide; hypromellose; macrogol 6000 - treatment of major depression. ,treatment of social anxiety disorder (social phobia). ,treatment of generalised anxiety disorder. ,treatment of obsessive-compulsive disorder.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - betahistine dihydrochloride, quantity: 16 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; mannitol; citric acid monohydrate; purified talc - meniere's syndrome as defined by the following core symptoms: - vertigo (with nausea/vomiting): - hearing loss (hardness of hearing): - tinnitus.